ForDoz Pharma Corp. Receives FDA Approval for DOXOrubicin Hydrochloride Liposome Injection

EAST WINDSOR, N.J., July 23, 2024 - ForDoz Pharma Corp., a private specialty pharmaceutical company, has achieved a significant milestone with the United States Food and Drug Administration (US FDA) approval of their DOXOrubicin Hydrochloride Liposome Injection. The approved dosages available are 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL). This liposomal injection is intended for treating patients with ovarian cancer and AIDS-related Kaposi's sarcoma. Additionally, in combination with bortezomib, it is indicated for treating patients with multiple myeloma.

James He, the Founder and CEO of ForDoz Pharma, emphasized the importance of this approval by stating, "The approval of DOXOrubicin Hydrochloride Liposome Injection signifies a major achievement for ForDoz Pharma as it represents our first liposomal injectable pharmaceutical product to be launched in the US market. Distribution will be managed by Lupin Pharmaceuticals, Inc."

ForDoz Pharma Corp. is a privately-owned specialty pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced sterile and complex injectable products. The company utilizes a proprietary technology platform and operates a unique cGMP sterile manufacturing facility. Their strategy focuses on expediting the development and production of complex injectables both for their own products and as a CDMO service provider for other companies.